32 results
The principal objective of the study is to determine if the performance of the new technique (magnetic tracer and magnetometer) is equivalent to the performance of the standard technique (patent blue dye and radioisotope, wire localization).The…
This large prospective multi-center cohort study aims to identify patient*s characteristics that significantly influence ovarian response to mild stimulation with a fixed dose of 75 IU recombinant FSH
The overall objective of this phase I/II three-part study is to evaluate the benefit of 12 weeks once daily dosing with ASP9521 in a population of patients with metastatic castrate resistant prostate cancer (CRPC) who have failed one or more lines…
Main objective of this study is to test the feasibility and to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer. Secondary…
Primary objectives:To confirm the lack of effect of 0.5 mg sublingual testosterone on physiological and subjective measures of sexual arousal in women with HSDD. Secondary objective:To confirm the lack of effect of 0.5 mg sublingual testosterone on…
To increase progression-free survival at 3 months.
The main objective of this feasibility study is to assess the treatment accuracy of MR-HIFU in patients with breast cancer using a dedicated MR-HIFU breast system. A secondary objective is to determine the safety.
Primary objective: To establish whether concomitant therapy of trastuzumab, bevacizumab with paclitaxel (regimen A) and/or trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab, and paclitaxel at progression (regimen B…
Primary objectives:- To improve the clinical effectiveness of the p53 synthetic long peptides vaccine by pre-administration of cyclophosphamide.- To evaluate the immunogenicity of a p53 synthetic long peptide vaccine when preceded by administration…
In this study we want to evaluate the safety, technical efficiency, and volume treatment capabilities of the Philips MR guided HIFU system in the treatment of patients with symptomatic uterine fibroids. This information is required for CE labelling…
Primary objective:- To assess the efficacy of niraparib in subjects with measurable mCRPC and who have either biallelic DNA-repair anomalies in BRCA (BRCA 1 and BRCA 2 or germline BRCA. Secondary objectives:- To assess the efficacy of niraparib in…
The overall study aim is to determine the efficacy rate of complete ablation for the most promising types of thermal ablation (RFA, MWA or CA) technique for patients with early stage breast cancer (cT1N0M0) without an extensive component of DCIS (…
The primary objective is efficacy of atezolizumab in advanced penile cancer patients measured by progression-free survival.
This study has been transitioned to CTIS with ID 2023-506987-15-00 check the CTIS register for the current data. 1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response…
Primary Objective: To assess the safety of the single flap peritoneum vaginoplasty procedure by studying adverse events and complications during, directly after and within 90 days of the operation. Secondary Objectives: - To assess short- (12 weeks…
Primary: * To assess Clinical Benefit Rate (CBR) in patients with mCRPC and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone OR enzalutamide) as second-line therapy.Secondary: * To formally compare CBR in both…
In the present study the clinical feasibility and safety of MR-guided focal boost radiotherapy for patients with locally advanced prostate cancer will be evaluated.
Primary objectiveThe primary objective for this phase IIa study is to investigate the feasibility, usability and safety of CLS MR-guided FLA in the treatment of prostate cancer.Secondary objectiveTo assess tumor response and functional outcomes
To investigate if surgery is feasible and safe in patients with newly diagnosed lymph node metastatic HSPCa who have received two cycles of (neo-adjuvant) systemic 177Lutetium (Lu)-labeled prostate-specific membrane antigen (PSMA) radioligand…
This study has been transitioned to CTIS with ID 2024-510634-41-00 check the CTIS register for the current data. Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or…